Drugs / HAL-MRE1
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03758456 | Nov 2018 → May 2019 | allergic rhinitis | HAL Allergy | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HAL-MRE1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03758456 ↗ |
| Modality | Protein / enzyme biologic | “containing aluminum hydroxide adsorbed modified allergens extracted from ragweed pollen” NCT03758456 ↗ |
| Route | Subcutaneous | “for subcutaneous administration” NCT03758456 ↗ |